Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine.

Payne, Rebecca P, Longet, Stephanie, Austin, James A, Skelly, Donal T, Dejnirattisai, Wanwisa, Adele, Sandra, Meardon, Naomi, Faustini, Sian E, Al-Taei, Saly, Moore, Shona C, Tipton, Tom, Hering, Luisa M, Angyal, Adrienn, Brown, Rebecca, Nicols, Alexander R, Gillson, Natalie, Dobson, Susan L, Amini, Ali, Supasa, Piyada, Cross, Andrew, Bridges-Webb, Alice, Reyes, Laura Silva, Linder, Aline, Sandhar, Gurjinder, Kilby, Jonathan A, Tyerman, Jessica K, Altmann, Thomas, Hornsby, Hailey, Whitham, Rachel, Phillips, Eloise, Malone, Tom, Hargreaves, Alexander, Shields, Adrian M, Saei, Ayoub, Foulkes, Sarah, Stafford, Lizzie, Johnson, Sile, Wootton, Daniel G, Conlon, Christopher P, Jeffery, Katie, Matthews, Philippa C, Frater, John, Deeks, Alexandra S, Pollard, Andrew J, Brown, Anthony, Rowland-Jones, Sarah L, Mongkolsapaya, Juthathip, Barnes, Eleanor, Hopkins, Susan, Hall, Victoria, Dold, Christina, Duncan, Christopher J A, Richter, Alex G, Carroll, Miles, Screaton, Gavin, de Silva, Thushan I, Turtle, Lance, Klenerman, Paul and Dunachie, Susanna (2021) Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell. ISSN 1097-4172. This article is available to all UHB staff and students login using UHB Athens Account. Register for Athens here - https://openathens.nice.org.uk/

Full text not available from this repository.
Official URL: https://www.cell.com/cell/fulltext/S0092-8674(21)0...

Abstract

Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was introduced in the United Kingdom to accelerate population coverage with a single dose. At this time, trial data were lacking, and we addressed this in a study of United Kingdom healthcare workers. The first vaccine dose induced protection from infection from the circulating alpha (B.1.1.7) variant over several weeks. In a substudy of 589 individuals, we show that this single dose induces severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody (NAb) responses and a sustained B and T cell response to the spike protein. NAb levels were higher after the extended dosing interval (6-14 weeks) compared with the conventional 3- to 4-week regimen, accompanied by enrichment of CD4 T cells expressing interleukin-2 (IL-2). Prior SARS-CoV-2 infection amplified and accelerated the response. These data on dynamic cellular and humoral responses indicate that extension of the dosing interval is an effective immunogenic protocol.

Item Type: Article
Additional Information: This article is available to all UHB staff and students login using UHB Athens Account. Register for Athens here - https://openathens.nice.org.uk/
Subjects: QW Microbiology. Immunology
Divisions: Clinical Support > Immunology
Related URLs:
Depositing User: Ms Willow Baylis
Date Deposited: 09 Nov 2021 09:49
Last Modified: 09 Nov 2021 09:49
URI: http://www.repository.uhblibrary.co.uk/id/eprint/4776

Actions (login required)

View Item View Item